ONCOLOGY

Scope & Guideline

Exploring the forefront of cancer treatment and research.

Introduction

Immerse yourself in the scholarly insights of ONCOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0030-2414
PublisherKARGER
Support Open AccessNo
CountrySwitzerland
TypeJournal
Convergefrom 1948 to 2024
AbbreviationONCOLOGY-BASEL / Oncology
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND

Aims and Scopes

The journal 'ONCOLOGY' is dedicated to advancing the field of cancer research and treatment. It encompasses a broad range of topics related to the diagnosis, treatment, and management of various cancers, focusing on both clinical and translational research.
  1. Clinical Research and Trials:
    The journal publishes studies related to clinical trials, treatment efficacy, and patient outcomes across various cancer types, emphasizing evidence-based approaches.
  2. Biomarkers and Genomic Profiling:
    Research focusing on the identification and validation of biomarkers for prognosis and treatment response, as well as genomic studies that explore the molecular underpinnings of cancer.
  3. Innovative Therapeutic Strategies:
    Papers that evaluate new therapeutic approaches, including immunotherapy, targeted therapies, and combination treatments, are a core focus, reflecting the journal's commitment to cutting-edge cancer care.
  4. Epidemiology and Risk Factors:
    The journal addresses the epidemiology of cancers, identifying risk factors and patterns of disease, which is crucial for public health and preventive strategies.
  5. Patient-Centered Care and Quality of Life:
    Research exploring the psychosocial aspects of cancer care, including quality of life, patient-reported outcomes, and supportive care, is emphasized to ensure holistic treatment approaches.
  6. Technological Innovations in Oncology:
    Studies that incorporate advanced technologies such as artificial intelligence and imaging techniques in cancer diagnosis and treatment are also featured, highlighting the journal's forward-looking perspective.
The journal 'ONCOLOGY' has shown a dynamic evolution in its focus areas, with several themes emerging as increasingly significant in recent publications. This reflects both advancements in cancer research and changing clinical practices.
  1. Immunotherapy and Checkpoint Inhibitors:
    There is a marked increase in studies evaluating the efficacy and safety of immunotherapies, particularly immune checkpoint inhibitors, reflecting their pivotal role in modern oncology.
  2. Personalized Medicine and Genomic Medicine:
    Research into personalized treatment approaches based on genomic profiling is trending, highlighting the importance of tailoring therapies to individual patient characteristics.
  3. Real-World Evidence and Outcomes Research:
    Emerging themes include the use of real-world data to assess treatment outcomes, patient experiences, and the effectiveness of therapies outside of clinical trial settings.
  4. Quality of Life and Patient-Reported Outcomes:
    An increasing number of studies are focusing on the quality of life, survivorship issues, and the psychosocial aspects of cancer treatment, emphasizing patient-centered care.
  5. Artificial Intelligence and Big Data in Oncology:
    The integration of artificial intelligence and big data analytics in cancer research and treatment planning is gaining momentum, indicating a transformative shift in the field.

Declining or Waning

While 'ONCOLOGY' continues to cover a wide array of topics, certain areas of focus have seen a decline in recent publications. These waning themes may indicate a shift in research priorities or the saturation of previously explored topics.
  1. Traditional Chemotherapy Approaches:
    Historically significant, traditional chemotherapy research is becoming less prominent as newer treatment modalities like immunotherapy and targeted therapy gain traction in the field.
  2. Single-Agent Studies:
    Research focusing solely on the efficacy of single-agent chemotherapy treatments has decreased, reflecting a broader understanding of the importance of combination therapies.
  3. Palliative Care Research:
    While still important, the volume of studies specifically centered on palliative care approaches and end-of-life issues has seen a decline, possibly overshadowed by advancements in curative treatment options.
  4. Basic Science and Laboratory Studies:
    There has been a noticeable shift away from basic science research towards more clinically relevant studies, indicating a move towards translational research that directly impacts patient care.
  5. Radiation Therapy Studies:
    The focus on traditional radiation therapy studies appears to be waning, with fewer publications compared to the rising interest in integrating radiation with systemic therapies.

Similar Journals

ACTA ONCOLOGICA

Elevating standards in oncology research and practice.
Publisher: Medical Journal Sweden ABISSN: 0284-186XFrequency: 12 issues/year

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

Clinical Lung Cancer

Exploring breakthroughs in lung cancer therapy and research.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Oncology in Clinical Practice

Transforming Patient Care with Cutting-Edge Research
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Therapeutic Advances in Medical Oncology

Advancing cancer care through innovative research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

JAMA Oncology

Uncovering the future of oncology through rigorous research.
Publisher: AMER MEDICAL ASSOCISSN: 2374-2437Frequency: 12 issues/year

JAMA Oncology, published by the American Medical Association, stands at the forefront of cancer research as a premier peer-reviewed journal in the field. With an ISSN of 2374-2437 and an impressive impact factor reflecting its critical insights, the journal has achieved a top-tier position, being ranked in the Q1 quartile for both Cancer Research and Oncology as of 2023, and demonstrating exceptional performance in Medicine as well. Spanning a converged publication period from 2015 through 2024, JAMA Oncology publishes cutting-edge research, clinical trials, and reviews that are pivotal in advancing our understanding and treatment of cancer. The journal's Scopus ranks highlight its global impact, placing it in the top deciles within its categories, ensuring that it remains a vital resource for oncologists, researchers, and students alike. While it currently does not offer open access, JAMA Oncology continues to provide invaluable contributions to the scientific community, promoting a deeper understanding of oncological challenges and breakthroughs.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Connecting Research and Practice in the Fight Against Cancer.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

eCancerMedicalScience

Transforming cancer treatment with cutting-edge research.
Publisher: eCancer Global FoundationISSN: 1754-6605Frequency:

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Delivering essential insights for the oncology community.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Cancers

Advancing cancer research for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Illuminating the path to better cancer and blood disorder management.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.